GlucoTrack (GCTK)
NASDAQ:GCTK
Top Page
GlucoTrack
(NASDAQ:GCTK)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.00
▲(3.63% Upside)
Action:ReiteratedDate:01/30/26
The score is primarily weighed down by very weak financial performance (minimal revenue, widening losses, rising cash burn, and negative equity). Technicals also detract due to a strong downtrend despite oversold readings. Corporate events provide some offset via improved IP positioning and added capital, but valuation remains constrained by ongoing losses and no dividend.
Positive Factors
Strengthened IP portfolio
The issuance of three patents for the continuous blood glucose monitoring platform creates durable barriers to entry around sensor chemistry, intravascular lead design and low-power electronics. This strengthens bargaining power with partners and defends commercialization efforts over the coming quarters.
Negative Factors
No meaningful revenue base
Sustained lack of revenue indicates the business has not achieved commercial traction. Without recurring sales, the company depends on funding to advance trials and commercialization, increasing execution and commercialization risk across a multi‑quarter horizon until meaningful revenue is established.
Read all positive and negative factors
Positive Factors
Negative Factors
Strengthened IP portfolio
The issuance of three patents for the continuous blood glucose monitoring platform creates durable barriers to entry around sensor chemistry, intravascular lead design and low-power electronics. This strengthens bargaining power with partners and defends commercialization efforts over the coming quarters.
Read all positive factors
GlucoTrack (GCTK) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.05M
Dividend YieldN/A
Average Volume (3M)2.54M
Price to Earnings (P/E)―
Beta (1Y)1.96
Revenue GrowthN/A
EPS Growth60.83%
CountryUS
Employees11
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-4.64
Shares Outstanding1,011,279
10 Day Avg. Volume100,775
30 Day Avg. Volume2,541,249
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-12.81
Price to Sales (P/S)0.00
P/FCF Ratio-13.22
Enterprise Value/Market Cap-6.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit172.62
Enterprise Value/Ebitda0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GlucoTrack Business Overview & Revenue Model
Company Description
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose mon...
How the Company Makes Money
GlucoTrack generates revenue primarily through the sale of its non-invasive glucose monitoring devices. The company's key revenue streams include direct sales of its products to consumers and healthcare providers, as well as potential licensing ag...
GlucoTrack Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
24
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -42.00K | -36.00K | -13.00K | -23.00K | 0.00 | -47.00K |
| EBITDA | -25.81M | -21.98M | -7.08M | -4.41M | -3.94M | -2.65M |
| Net Income | -25.85M | -22.60M | -7.10M | -4.43M | -4.07M | -2.70M |
Balance Sheet | ||||||
| Total Assets | 8.29M | 5.93M | 4.91M | 2.44M | 6.26M | 10.61M |
| Cash, Cash Equivalents and Short-Term Investments | 7.87M | 5.62M | 4.49M | 2.31M | 6.06M | 9.82M |
| Total Debt | 40.00K | 267.00K | 196.00K | 195.00K | 250.00K | 363.00K |
| Total Liabilities | 5.54M | 18.93M | 1.71M | 1.21M | 1.11M | 1.62M |
| Stockholders Equity | 2.75M | -13.00M | 3.20M | 1.23M | 5.16M | 8.98M |
Cash Flow | ||||||
| Free Cash Flow | -14.88M | -12.59M | -6.56M | -3.73M | -3.77M | -3.55M |
| Operating Cash Flow | -14.80M | -12.49M | -6.56M | -3.73M | -3.77M | -3.50M |
| Investing Cash Flow | -76.00K | -104.00K | 0.00 | 1.00K | -1.00K | -53.00K |
| Financing Cash Flow | 22.33M | 13.74M | 8.73M | 0.00 | 0.00 | 13.01M |
GlucoTrack Technical Analysis
Negative
1.93
Price Trends
1.98
Negative
3.58
Negative
4.97
Negative
Market Momentum
-0.26
Negative
19.93
Positive
13.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GCTK, the sentiment is Negative. The current price of 1.9300000000000002 is above the 20-day moving average (MA) of 1.30, below the 50-day MA of 1.98, and below the 200-day MA of 4.97, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 19.93 is Positive, neither overbought nor oversold. The STOCH value of 13.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GCTK.
GlucoTrack Risk Analysis
GlucoTrack disclosed 35 risk factors in its most recent earnings report. GlucoTrack reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
GlucoTrack Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $39.13M | -1.12 | -85.01% | ― | -16.59% | 43.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.47M | -2.02 | ― | ― | ― | ― | |
42 Neutral | $1.05M | -0.36 | ― | ― | ― | 60.83% | |
41 Neutral | $30.51M | -0.61 | -764.17% | ― | 63.53% | 12.49% |
* Healthcare Sector Average
GCTK
GlucoTrack
1.04
-13.50
-92.85%
EKSO
EKSO BIONICS
10.98
4.24
62.91%
FEMY
Femasys
0.51
-1.01
-66.32%
WOK
WORK Medical Technology Group LTD
1.21
-5,898.80
-99.98%
GlucoTrack Corporate Events
Business Operations and StrategyProduct-Related Announcements
GlucoTrack Strengthens IP for Implantable Glucose Monitoring Platform
Positive
Jan 29, 2026
On January 29, 2026, Glucotrack, Inc. announced that the U.S. Patent and Trademark Office had issued three patents in late 2025 covering key technologies underpinning its fully implantable continuous blood glucose monitoring platform, including pr...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
GlucoTrack strengthens capital position with new private placement
Positive
Dec 31, 2025
On December 29, 2025, Glucotrack, Inc. entered into a securities purchase agreement with a single institutional investor for a private placement of pre-funded warrants and common warrants (or common stock equivalents) priced at-the-market under Na...
Business Operations and StrategyRegulatory Filings and Compliance
GlucoTrack Issues Investor Presentation Under Regulation FD
Neutral
Dec 29, 2025
On December 29, 2025, GlucoTrack, Inc., a Delaware corporation, issued an investor presentation to its shareholders and the broader market. The materials, which were provided as an investor update rather than a formal securities filing, were expli...
Private Placements and FinancingShareholder Meetings
GlucoTrack Announces Special Shareholders Meeting for Equity Deal
Neutral
Nov 3, 2025
On November 3, 2025, Glucotrack, Inc. announced the reconvening of a Special Meeting of Shareholders on November 7, 2025, to vote on an Equity Purchase Agreement with Sixth Borough Capital Fund. This agreement, compliant with NASDAQ Listing Rule 5...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.